SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

BWAY

BrainsWay
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The combination of strong top-line growth, expanding profitability, rising backlog, and new FDA clearances suggests accelerating commercial momentum. Traders should monitor execution against the aggressive 2026 EBITDA guidance and adoption of the new adolescent and SWIFT protocols as key catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.77
T+0 close · Mar 11, 2026 · via day close
Latest settled
+1.96%
T+60 · $14.04
Vs SPY
−9.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $13.77entry
  2. T+1 · 8mo ago −0.22%α +1.27% · $13.74
  3. T+5 · 8mo ago −2.40%α −0.21% · $13.44
  4. T+20 · 7mo ago +3.85%α +3.33% · $14.30
  5. T+60 · 5mo ago +1.96%α −9.56% · $14.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay reported strong Q4 and full-year 2025 results with 27% YoY revenue growth to $52.2 million, net income up 161% to $7.6 million, and raised 2026 guidance projecting $66–68 million in revenue (27–30% growth) and Adjusted EBITDA of $12–14 million (86–100% growth). The company also secured FDA clearances for adolescent depression and an accelerated treatment protocol, expanding its market potential.

Key Financial Metrics

Revenue
$52.2M
+27.0% YoY
EPS
$0.20
Guidance
$66M-$68M
raised

Key Facts

  • Q4 2025 revenue: $14.5M (+27% YoY)
  • Full-year 2025 revenue: $52.2M (+27% YoY)
  • Full-year 2025 net income: $7.6M (+161% YoY)
  • Adjusted EBITDA for 2025: $7.0M (+55% YoY)
  • Remaining performance obligations up 43% to $70M
  • 2026 revenue guidance: $66M–$68M (27–30% growth)
  • 2026 Adjusted EBITDA guidance: $12M–$14M (86–100% growth)
  • FDA cleared Deep TMS for adolescents (15–21) with MDD and approved accelerated SWIFT™ protocol

Financial Impact

Revenue growth accelerating at scale with expanding margins; $18M midpoint increase in Adjusted EBITDA expected in 2026

revenuenet incomeebitdaoperating leveragecash flow

Risk Factors

  • Forward-looking guidance may not be achieved
  • High growth expectations already priced into stock (OTC market, $961M market cap)
  • Cash balance declined slightly despite strong net income due to working capital outflows

Market Snapshot

Exchange
OTC

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253665

US Market Status

Market Closed · Opens Tue (17h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026